Background Complement pathway inhibition may provide benefit for severe acute
respiratory illnesses caused by viral infections such as COVID-19. We present results from a …

Background Complement activation contributes to lung dysfunction in coronavirus disease
2019 (COVID-19). We assessed whether C5 blockade with eculizumab could improve …

Abstract OBJECTIVE: SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2)-
related pneumonia, referred to as COVID-19 (Coronavirus Disease 19), is a public health …

Growing clinical evidence has implicated complement as a pivotal driver of COVID-19
immunopathology. Deregulated complement activation may fuel cytokine-driven hyper …

Since the report of the first cases in December 2019, infection with the severe acute
respiratory coronavirus 2 (SARS-CoV-2) commonly referred as COVID-19 has become a …

Respiratory failure and acute kidney injury (AKI) are associated with high mortality in SARS-
CoV-2-associated Coronavirus disease 2019 (COVID-19). These manifestations are linked …

Background Severe COVID-19 is characterised by inflammation and coagulation in the
presence of complement system activation. We aimed to explore the potential benefit and …

Background The pathophysiology of COVID-19 includes immune-mediated
hyperinflammation, which could potentially lead to respiratory failure and death. Granulocyte …

Abstract Objectives Coronavirus disease 2019 (COVID-19) is caused by the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). Umifenovir (Arbidol®) is an antiviral …

Respiratory failure in the acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
pandemic is hypothesized to be driven by an overreacting innate immune response, where …